{
    "2018-11-26": [
        [
            {
                "time": "",
                "original_text": "复星医药(02196)子公司用于治疗胃癌和乳腺癌新药获国家食药监临床试验注册审评受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "胃癌",
                        "乳腺癌",
                        "新药",
                        "临床试验",
                        "国家食药监"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2022-11-30",
                "original_text": "[快讯]复星医药71万股限售股11月30日解禁",
                "features": {
                    "keywords": [
                        "复星医药",
                        "限售股",
                        "解禁"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "复星医药：子公司抗癌新药临床试验申请获受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "抗癌新药",
                        "临床试验",
                        "申请受理"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "专家诊股：龙辉国际走势偏弱  复星医药26止损",
                "features": {
                    "keywords": [
                        "龙辉国际",
                        "复星医药",
                        "走势偏弱",
                        "止损"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报:药店分级意见稿出台,坚守细分景气龙头",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业周报",
                        "药店分级",
                        "意见稿",
                        "细分景气龙头"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}